PLC-ZD55-IL-24(PLC-ZD55-IL-24) - 药物靶点：IL-24_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

溶瘤病毒

别名

靶点

IL-24

作用机制

IL-24调节剂(白细胞介素24调节剂)

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症-

原研机构

上海仁玑医院管理有限公司

在研机构

上海仁玑医院管理有限公司

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 PLC-ZD55-IL-24 相关的临床结果

登录后查看更多信息

100 项与 PLC-ZD55-IL-24 相关的转化医学

登录后查看更多信息

100 项与 PLC-ZD55-IL-24 相关的专利（医药）

登录后查看更多信息

1

项与 PLC-ZD55-IL-24 相关的文献（医药）

2016-12-27·ACS Nano1区 · 材料科学

Oncolytic Adenovirus Complexes Coated with Lipids and Calcium Phosphate for Cancer Gene Therapy

1区 · 材料科学

Article

作者: Sun, Ying ; Ding, Li ; Chen, Jianhua ; Chu, Liang ; Duan, Yourong ; Liu, Xin-Yuan ; Li, Rongxin ; Yuan, Sujing ; Ni, Aimin ; Gao, Pei

Oncolytic adenovirus (Onco^Ad) is a promising therapeutic agent for treating cancer. However, the therapeutic potential of Onco^Ad is hindered by hepatic sequestration and the host immune response in vivo. Here, we constructed a PEG/Lipids/calcium phosphate (CaP)-Onco^Ad (PLC-Onco^Ad) delivery system for ZD55-IL-24, an oncolytic adenovirus that carries the IL-24 gene. The negatively charged PLC-ZD55-IL-24 were disperse and resisted serum-induced aggregation. Compared to naked ZD55-IL-24, the systemic administration of PLC-ZD55-IL-24 in BALB/c mice resulted in reduced liver sequestration and systemic toxicity and evaded the innate immune response. In addition, masking the surface of Onco^Ad protected it from neutralization by pre-existing neutralizing antibody. PLC-Onco^Ad achieved efficient targeted delivery in Huh-7-bearing nude mice, and intravenous administration of a high dose of PLC-ZD55-IL-24 increased therapeutic efficacy without inducing toxicity. The developed PLC-Onco^Ad delivery system represents a promising improvement for oncolytic adenovirus-based cancer gene therapy in vivo.

100 项与 PLC-ZD55-IL-24 相关的药物交易

登录后查看更多信息